Crispr Therapeutics AG vs Warner Music Group Corp — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 3.1× Crispr Therapeutics AG's market cap, and Warner Music Group Corp pays a 2.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Warner Music Group Corp for 96 Days on average.
| CRSP | WMG | |
|---|---|---|
Market Cap | $4.88B | $15.12B |
Volume | 2,861,747 | 2,966,414 |
Sector | Health | Media |
52-Week High | $74.92 | $34.72 |
52-Week Low | $44.34 | $23.65 |
Typical Hold Time | 77 Days | 96 Days |
Enterprise Value | $3.30B | $19.42B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Warner Music Group (WMG) trades at $28.72, up 1.99% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and maintains a robust gross profit margin of 45.77%. Recent news highlights strategic AI partnerships and licensing renewals, signaling growth initiatives. Revenue has grown from $5.9B in 2022 to $6.7B in 2025, with a projected increase to $7.3B in 2026.
The outlook for WMG is positive, driven by earnings beats, analyst optimism, and AI-driven content curation opportunities. Key risks include competitive pressures in the music industry and execution challenges amid leadership changes. The consensus price target of $39.50 implies significant upside, but investors should monitor margin trends and competitive dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →